|
|
|
| Analysis of participation degree of traditional Chinese medicine in lung malignant tumor cases from 30 hospitals in Beijing |
| LIU Liming1 CHENG Wei1,2 MAN Xiaowei1,2 ZHAO Liying1,2 YANG Hong1 XU Yue1 MA Lin1 JIANG Yan1,2 |
1.Beijing University of Chinese Medicine, Beijing 100029, China;
2.National Institute of Chinese Medicine Development and Strategy, Beijing University of Chinese Medicine, Beijing 100029, China |
|
|
|
Abstract Objective To explore the main factors that affect patients’ participation in traditional Chinese medicine, and to provide references for traditional Chinese medicine to participate in the treatment of lung malignant tumors. Methods Taking socio-demographic factors into consideration, a total of 30 hospitals in Beijing from January to December, 2016 were selected. The information of patients with lung malignant tumors was extracted from them, and the basic information, hospitalization status, and participation in traditional Chinese medicine were extracted. The factors affecting participation were analyzed statistically. Results A total of 12 163 hospitalized patients with lung malignant tumors were collected, and the effective number of cases was 12 099 cases. Among them, the proportion of male patients was higher than that of females, and the proportion of patients aged >60-80 years was the largest. The payment method was mainly urban employee basic medical insurance, and the proportion of patients in tertiary hospitals was much higher. In a secondary hospital, the average hospital stay was (11.62±9.39) days. The overall participation rate of traditional Chinese medicine in patients with lung malignant tumors was 69.30%. The single-factor analysis showed that the participation rate of traditional Chinese medicine was statistically significant in different genders, ages, payment methods, hospital levels and length of stay in hospital (P ＜ 0.05). The logistic regression results showed that payment method (OR = 1.864), hospital level (OR = 1.435) and hospital stay (OR = 1.047) were the main factors affecting the participation of traditional Chinese medicine in patients with lung malignant tumors (P ＜ 0.05). Conclusion The participation of traditional Chinese medicine in the treatment of lung malignant tumors can be further enhanced by rationally guiding the flow of medical treatment, exploring the characteristics of traditional Chinese medicine diagnosis and treatment methods, and improving the price system of traditional Chinese medicine services, which can reduce the cost burden of lung cancer while exerting the advantages of traditional Chinese medicine.
|
|
|
|
|
|
[1] 张小英，韦惠杰，朱萧，等.肺癌患者经济负担及影响因素分析[J].世界最新医学信息文摘，2019，19（17）：196， 199.
[2] Qiao L，Ma DL，Lv H，et al. Metabolic syndrome and the incidence of lung cancer：a meta-analysis of cohort studies [J]. Diabetol Metab Syndr，2020，12（1）：95.
[3] 陈颖兰，万轲.女性肺癌发病率正快速升高，这些危险因素须警惕[J].祝您健康，2020（8）：22-23.
[4] 杨玉霞.济南市某三甲医院肺癌患者住院费用变动趋势及影响因素分析[D].济南：山东大学，2019.
[5] 王霞.基于数据挖掘技术的肺癌风险评估与诊断及组织分型系统研究[D].郑州：郑州大学，2019.
[6] 庞震苗，杨婷婷，徐庆锋.我国中医类诊所运营现状及发展对策探讨[J].中国医院管理，2017，37（6）：17-19.
[7] 钟伶.近10年全球传统医学发展态势与中医药研究热点分析[J].中华中医药杂志，2020，35（8）：4088-4093.
[8] 中医药健康服务发展规划（2015—2020年）[N].中国中医药报，2015-05-08（002）.
[9] 中共中央国务院印发《“健康中国2030”规划纲要》[J].中华人民共和国国务院公报，2016（32）：5-20.
[10] 崔婷婷，熊季霞.基于集聚度的我国中医药卫生资源配置公平性分析[J].中国医院管理，2017，37（7）：18-20，61.
[11] 王青云.《2019年我国卫生健康事业发展统计公报》公布[J].中医药管理杂志，2020，28（11）：3.
[12] 王世华.东北地区中医药治疗肺癌患者住院费用构成及其影响因素评价研究[D].北京：中国中医科学院，2019.
[13] 陈勤华，肖文莉，罗曲，等.肺癌中医护理方案临床应用效果评价[J].当代护士：下旬刊，2018，25（9）：1-3.
[14] 郭春梅.肺癌中医辨证施护方案对Ⅲ-Ⅳ期肺癌患者预后和生活质量的影响分析[J].实用临床护理学电子杂志，2018，3（32）：19，24.
[15] 李蕊白，王婧，吕鹏，等.从肝论治肺癌的优势[J].世界中医药，2018，13（5）：1297-1300.
[16] 罗友晖，景琳，张瑞华，等.四川省中医医院反应性水平调查分析[J].中国医院管理，2006（7）：16-18.
[17] 黄龙斌.公立医院医疗服务价格改革对中医医院的影响——以S省中医医院为例[J].西部财会，2019（1）：65-68.
[18] 马睦（Almahmoud Monaf）.上海市中医药医疗服务发展评估研究[D].上海：上海交通大学，2018.
[19] 宋会颖，张虹.中医药治疗原发性支气管肺癌概况[J].河北中医，2018，40（10）：1586-1590，1595.
[20] 刘华清，陈云凤，周章兵，等.肺癌的中医治疗概况[J].世界最新医学信息文摘，2017，17（A4）：14-15.
[21] 梁启廉.医疗付费制度对住院患者就医行为的影响研究[D].南昌：江西财经大学，2017.
[22] 徐张燕.某三甲医院肺癌病人住院费用及其影响因素分析[D].南京：南京医科大学，2015.
[23] 黄诗尧，杨练，孙群，等.四川省恶性肿瘤患者住院费用及影响因素研究[J].现代医院管理，2018，16（2）：61-64.
[24] 金雯，张岩曦，徐周.基于ARIMA乘积季节模型预测恶性肿瘤住院量、住院费用及平均住院时间[J].现代医院，2019，19（3）：383-389.
[25] 王淑强，钟文洲.结直肠癌患者住院费用构成分布及其影响因素分析[J].中国医药导报，2019，16（23）：118-121.
[26] 国家发展改革委，卫生部，国家中医药管理局.关于规范医疗服务价格管理及有关问题的通知[EB/OL].（2012-05-04）.http://www.gov.cn/gzdt/2012-05/10/content_2133932.htm.
[27] 党海霞，图雅，杨永生，等.中医药服务价格现状抽样调查及调整策略建议[J].中国卫生经济，2013，32（8）：23-25. |
|
|
|
